Baxter Grabs FDA Clearance for Bioactive Bone Graft

Baxter has been granted 510(k) clearance by the FDA for its Altapore Shape bioactive bone graft, a new addition to the company’s Altapore product line that comes in four different configurations.

The bone graft, which is designed to improve bone growth and encourage fusion following surgery, comes in three different sized cylinders (1.6 ml, 2.6 ml and 8 ml) and a single 15.8 ml strip to allow surgeons to mold the product to their needs.

In a clinical trial of the bone graft in 102 patients, 86.3 percent of participants saw successful fusion after one year.